-
401
Prevalence of bed falls among inpatients in Iranian hospitals: A meta-analysis
Published 2025-06-01Get full text
Article -
402
-
403
-
404
-
405
Impact of Oxycodone HCl Extended-release Formulary Restrictions on Extended-release Opioid Market Share, Healthcare Resource Utilization and Costs in Commercial and Medicare Plans
Published 2017-07-01“…**Background:** Previous research demonstrated that utilization management (UM) such as prior authorization (PA) or non-formulary (NF) restrictions may reduce pharmacy costs when designed and applied appropriately to certain drug classes. …”
Get full text
Article -
406
Lung-homing nanoliposomes for early intervention in NETosis and inflammation during acute lung injury
Published 2025-02-01Get full text
Article -
407
-
408
-
409
Economic Burden of HIV in a Commercially Insured Population in the United States
Published 2023-01-01“…All-cause costs PPPM for adults with PrEP were $1761 ($1938), with pharmacy costs accounting for 71%. **Conclusions:** Despite advances in ART, patients with newly diagnosed HIV and at-risk patients receiving PrEP continue to incur HRU costs. …”
Get full text
Article -
410
Leveraging AlphaFold for innovation and sustainable health research in Africa
Published 2025-02-01Get full text
Article -
411
War-related eye trauma: a study of civilian and military cases from Ukraine's ongoing conflict
Published 2025-02-01Get full text
Article -
412
-
413
-
414
Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn’s Disease Initiating Biologics With 3 Years of Follow-Up
Published 2023-11-01“…**Methods:** This retrospective observational study was conducted using the STATinMED RWD Insights all-payer medical and pharmacy data. Adult patients with at least 1 CD medical claim and at least 1 medical/pharmacy claim for a biologic (adalimumab \[ADA\], certolizumab pegol (CZP), infliximab \[IFX\] and its biosimilar products \[IFX-BS\], ustekinumab \[UST\], and vedolizumab \[VDZ\]) between September 2016 and October 2018 were identified. …”
Get full text
Article -
415
-
416
-
417
Discovery of the bacterial HslV protease activators as lead molecules with novel mode of action
Published 2025-02-01Get full text
Article -
418
-
419
Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata
Published 2022-07-01“…Post-index, AT/AU vs controls had more outpatient (14.5 vs 7.1) and dermatologist (3.6 vs 0.3) visits, higher mean plan costs ($9397 vs $2267), including medical ($7480 vs $1780) and pharmacy ($1918 vs $487) costs, and higher OOP costs ($2081 vs $751) (all _P_<.001). …”
Get full text
Article -
420
Sustainable Ultrasound-Assisted Solid-Phase peptide synthesis (SUS-SPPS): Less Waste, more efficiency
Published 2025-03-01Get full text
Article